Erik Digman Wiklund

Erik Digman Wiklund

Company: Targovax

Job title: Chief Executive Officer


Clinical Efficacy & Immune Activation Demonstrated By Oncolytic Adenovirus ONCOS-102 In Solid Tumors 12:30 pm

Robust clinical activity of ONCOS-102 in combination with both anti-PD1 and chemotherapy has been observed in several solid tumor types ONCOS-102 drives broad and persisting immune responses in responding patients Extended dosing regimen drives stronger immune activation and increased systemic activityRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.